IPN Ipsen SA

Ipsen S.A. publishes its 2023 Half-Year Financial Report

Ipsen S.A. publishes its 2023 Half-Year Financial Report

Ipsen S.A. publishes its 2023 Half-Year Financial Report

Attachment



EN
27/07/2023

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025  Aggregated presentation by day and by market               Statement of transactions in own shares from June 16th to June 20th 2025 Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)  IPSEN549300M6SGDPB4Z94P1116/06/2025FR0010259150   140   103,60AQEUIPSEN549300M6SGDPB4Z94P1116/06/2025FR0010259150   221   103,50CCXEIPSEN549300M6SGDPB4Z94P111...

June 24, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règleme...

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2025  Présentation agrégée par jour et par marché           Déclaration des transactions sur actions propres réalisées du 16 juin au 20 juin 2025         Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code identifiant de l'instrument financier Volume total journalier (en nombre de titres) Prix pondéré moyen journalier d'acquisition Code identifiant marché IPSEN 549300M6SGDPB4Z94P11 16/06/2025 FR0010259150    140    103,60 AQEU   IPSEN 549300M6SGDPB...

June 24, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Cabometyx® in previously trea...

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2Recommendation based on CABINET Phase III trial results, which demonstrated statistically significant and clinically meaningful reductions in risk of disease progression or death with Cabometyx versus placebo3,4European Commission decision expected Q3...

June 20, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Cabometyx® dans les tumeurs ...

Ipsen reçoit un avis positif du CHMP pour Cabometyx® dans les tumeurs neuroendocrines avancées précédemment traitées S’il est approuvé, Cabometyx® sera le premier et unique traitement systémique autorisé dans l’Union européenne pour les tumeurs neuroendocrines précédemment traitées, indépendamment de la localisation de la tumeur, de sa gravité et de l’administration ou non d’un traitement systémique auparavant, autre qu’un traitement par analogue de la somatostatine1, 2Les recommandations se basent sur les résultats de l’étude de Phase III CABINET qui ont démontré une réduction significativ...

June 20, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025 Aggregated presentation by day and by market Statement of transactions in own shares from June 09th to June 13th 2025       Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket         (MIC Code) IPSEN549300M6SGDPB4Z94P1109/06/2025FR0010259150   320   104,26875AQEUIPSEN549300M6SGDPB4Z94P1109/06/2025FR0010259150  1 050   104,1799CCXEIPSEN549300M6SGDPB4Z94P...

June 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch